Johnson Pharmacare (532154) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
30 Oct, 2025Executive summary
Board approved unaudited financial results for the quarter and half year ended September 30, 2024 at the meeting held on November 13, 2024.
Statutory auditors conducted a limited review and found no material misstatements in the financial statements.
Financial highlights
Reported a net loss of ₹0.08 lakh for Q2 FY25, compared to a net loss of ₹0.18 lakh in Q2 FY24.
Net loss for the half year ended September 30, 2024 was ₹4.07 lakh, compared to ₹18.96 lakh for the same period last year.
Total income from operations was negligible for both the quarter and half year.
Basic and diluted EPS for the quarter and half year were both ₹(0.00).
Key financial ratios and metrics
Paid-up equity share capital stood at ₹5,500 lakh as of September 30, 2024.
Other equity was ₹171.23 lakh as of September 30, 2024.
Total assets were ₹5,982.90 lakh as of September 30, 2024.
Latest events from Johnson Pharmacare
- Net loss increased to ₹110.31 lakhs on flat revenue, with EPS at ₹(0.02) for the quarter.532154
Q1 26/27 - FY26 saw a sharp net loss, negative cash flows, and major doubts about financial viability.532154Q4 25/26
- New auditor and independent director appointed, with all regulatory confirmations in place.532154Q3 25/26
- No revenue and continued net losses reported for the quarter ended September 30, 2025.532154Q2 25/26
- Net loss of ₹3.99 lakhs on revenue of ₹3.99 lakhs reported for Q1 FY25.532154Q1 24/25
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/25
- Net loss increased to Rs. 5.34 lakhs for Q1 FY26 as income declined and expenses rose.532154Q1 25/26
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/25